|本期目录/Table of Contents|





Molecular biological mechanism of aortic calcification and prospect
(1.安徽医科大学无锡临床学院心血管内科,江苏 无锡 214044;2.中国人民解放军第101医院心血管内科,江苏 无锡 214044)
CHENG Zhi-yuan1 ZONG Gang-jun2
(1.Department of Cardiology, Wuxi Clinical Hospital, Anhui Medical University, Wuxi 214044, Jiangsu, China; 2.Department of Cardiology, PLA 101 Hospital, Wuxi 214044, Jiangsu, China)
calcified aortic valve disease valve interstitial cells osteoporosis Mechanism of molecular biology treatment
Calcific aortic valve disease (CAVD) is the most common valvular heart disease of the elderly. As life expectancy increases, prevalence of CAVD is expected to rise. One third of our elderly population has echocardiographic or radiological evidence of calcific aortic valve sclerosis, an early and subclinical form of CAVD. Age, gender, smoking, tobacco use, hypercholesterolemia, hypertension, and type II diabetes mellitus all contribute to the risk of the disease that has worldwide distribution. On progression to its most severe form, calcific aortic stenosis, CAVD can be devastating and 2% of the individuals >60 years are affected by calcific aortic stenosis to the extent that surgical intervention is required. No effective pharmacotherapies currently exist for treating those at risk for clinical progression. In the initial stages, the pathogenesis is similar to atherosclerosis, characterized by basement membrane disruption, inflammation, cell infiltration, lipid deposition, and calcification. Presence of osteopontin in calcified aortic valves suggests pathological calcification and bone formation in these calcified valves. Calcific mineral deposition within the soft cardiovascular tissues disrupts the normal biomechanical function of these tissues, leading to complications, including heart failure, myocardial infarction, and stroke. In this review, our investigation highlights current understanding of CAVD, emphasizing molecular and cellular aspects of its recent research and reviewing newer treatment strategies.


[1]Rajamannan NM,Evans FJ,Aikawa E,et al.Calcific aortic valve disease:not simply a degenerative process:A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group.Executive summary:Calcific aortic valve disease-2011 update[J].Circulation,2011,124(16):1783-1791.

[2]New SE,Aikawa E.Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification[J].Circ Res,2011,108(11):1381-1391.

[3]Smith JG,Luk K,Schulz CA,et al.Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis[J].JAMA,2014,312(17):1764-1771.

[4]Thanassoulis G,Campbell CY,Owens DS,et al.Genetic associations with valvular calcification and aortic stenosis[J].N Engl J Med,2013,368(6):503-512.

[5]Otto CM,Kuusisto J,Reichenbach DD,et al.Characterization of the early lesion of‘degenerative’valvular aortic stenosis.Histological and immunohistochemical studies[J].Circulation,1994,90(2):844-853.

[6]Proudfoot D,Skepper JN,Hegyi L,et al.Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies[J].Circ Res,2000,87(11):1055-1062.

[7]Kim KM.Calcification of matrix vesicles in human aortic valve and aortic media[J].Fed Proc 1976,35(2):156-162.

[8]Nadra I,Mason JC,Philippidis P,et al.Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase C and MAP kinase pathways:a vicious cycle of inflammation and arterial calcification?[J].Circ Res,2005,96(12):1248-1256.

[9]O’Brien KD,Shavelle DM,Caulfield MT,et al.Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma[J].Circulation,2002,106(17):2224-2230.

[10]Peltonen T,Napankangas J,Ohtonen P,et al.(Pro)renin receptors and angiotensin converting enzyme 2/angiotensin-(1-7)/Mas receptor axis in human aortic valve stenosis[J].Atherosclerosis,2011,216(1):35-43.

[11]Fondard O,Detaint D,Iung B,et al.Extracellular matrix remodelling in human aortic valve disease:the role of matrix metalloproteinases and their tissue inhibitors[J].Eur Heart J,2005,26(13):1333-1341.

[12]Kochtebane N,Choqueux C,Michel JB,et al.Aortic stenosis and extracellular matrix remodeling[J].Biol Aujourdhui,2012,206(2):135-143.

[13]Naik V,Leaf EM,Hu JH,et al.Sources of cells that contribute to atherosclerotic intimal calcification: an in vivo genetic fate mapping study[J].Cardiovasc Res,2012,94(3):545-554.

[14]Demer LL,Tintut Y.Inflammatory,metabolic, and genetic mechanisms of vascular calcification[J].Arterioscler Thromb Vasc Biol,2014,34(4):715-723.

[15]Hutcheson JD,Goettsch C,Pham T,et al.Enrichment of calcifying extracellular vesicles using density-based ultracentrifugation protocol[J].J Extracell Vesicles,2014,3(5):25129.

[16]Wylie-Sears J,Aikawa E,Levine RA,et al.Mitral valve endothelial cells with osteogenic differentiation potential[J].Arterioscler Thromb Vasc Biol,2011,31(3):598-607.

[17]Cheng SL,Shao JS,Behrmann A,et al.Dkk1 and MSX2-Wnt7b signaling reciprocally regulate the endothelial-mesenchymal transition in aortic endothelial cells[J].Arterioscler Thromb Vasc Biol,2013,33(7):1679-1689.

[18]Merryman WD,Lukoff HD,Long RA,et al.Synergistic effects of cyclic tension and transforming growth factor-beta1 on the aortic valve myofibroblast[J].Cardiovasc Pathol,2007,16(5):268-276.

[19]Yip CY,Chen JH,Zhao R,et al.Simmons CA.Calcification by valve interstitial cells is regulated by the stiffness of the extracellular matrix[J].Arterioscler Thromb Vasc Biol,2009,29(6):936-942.

[20]Hutcheson JD,Chen J,Sewell-Loftin MK,et al.Cadherin-11 regulates cell-cell tension necessary for calcific nodule formation by valvular myofibroblasts[J].Arterioscler Thromb Vasc Biol,2013,33(1): 114-120.

[21]Rajamannan NM,Subramaniam M,Rickard D,et al.Human aortic valve calcification is associated with an osteoblast phenotype[J].3Circulation3,2003,107(17):2181-2184.

[22]Liu AC,Joag VR,Gotlieb AI.The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology[J].Am J Pathol,2007,171(5):1407-1418.

[23]Tintut Y,Demer L.Role of osteoprotegerin and its ligands and competing receptors in atherosclerotic calcification[J].J Investig Med,2006,54(7):395-401.

[24]Towler DA.Molecular and cellular aspects of calcific aortic valve disease[J].Circ Res,2013,113(2):198-208.

[25]Garg V,Muth AN,Ransom JF,et al.Mutations in NOTCH1 cause aortic valve disease[J].Nature,2005,437(7056):270-274.

[26]Caira FC,Stock SR,Gleason TG,et al.Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation[J].J Am Coll Cardiol,2006,47(8):1707-1712.

[27]Shao JS,Cheng SL,Pingsterhaus JM,et al.Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals[J].J Clin Invest,2005,115(5):1210-1220.

[28]Pfister R,Michels G,Sharp SJ,et al.Inverse association between bone mineral density and risk of aortic stenosis in men and women in EPIC-Norfolk prospective study[J].Int J Cardiol,2015,178(15):29-30.

[29]D’Amelio P,Isaia G,Isaia GC.The osteoprotegerin/RANK/RANKL system:a bone key to vascular disease[J].J Endocrinol Invest,2009,32(4):6-9.

[30]Kaden JJ,Bickelhaupt S,Grobholz R,et al.Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification[J].J Mol Cell Cardiol,2004,36(1):57-66.

[31]Price PA,Faus SA,Williamson MK.Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption[J].Arterioscler Thromb Vasc Biol,2001,21(5): 817-824.

[32]Sansoni P,Passeri G,Fagnoni F,et al.Inhibition of antigen-presenting cell function by alendronate in vitro[J].J Bone Miner Res,1995,10(11):1719-1725.

[33]Lai TJ,Hsu SF,Li TM,et al.Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell line[J].Acta Pharmacol Sin,2007,28(8):1231-1235.

[34]Vassalle C,Mazzone A.Bone loss and vascular calcification:A bi-directional interplay?[J].Vascul Pharmacol,2016,86(4):77-86.

[35]Toussaint ND,Elder GJ,Kerr PG. Bisphosphonates in chronic kidney disease;balancing potential benefits and adverse effects on bone and soft tissue[J].Clin J Am Soc Nephrol,2009,4(1):221-233.

[36]Kranenburg G,Bartstra JW,Weijmans M,et al.Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis[J].Atherosclerosis,2016,252(24):106-115.


收稿日期:2016-12-02.基金项目:国家自然科学基金项目资助(81371657) 通讯作者:宗刚军,副主任医师,主要从事心脏瓣膜病基础与临床研究 Email:zonggj@163.com 作者简介:程治源,硕士生 Email:15205215338@163.com
更新日期/Last Update: 1900-01-01